MedTrace Logo

Home or Away From Home - Descriptive Interviews (Aim 2)

NCT02794207 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2020-01-27

Study results available
· View outcomes & findings →

Summary

The primary objectives of this study are to identify what outcomes related to the management of neutropenia are most important to children with AML and their caregivers. Patients who have completed treatment for AML and their caregivers will be interviewed in order to better understand the impact of neutropenia management on children with AML and their families. The primary outcome of these interviews is to identify patient-centered outcomes related to neutropenia management to include in a subsequent comparative-effectiveness analysis. Investigators will use these data to develop a structured survey for administration to prospectively identified patients in subsequent studies.

Conditions

  • Pediatric Acute Myeloid Leukemia

Sponsors & Collaborators

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • Primary Children's Hospital

    collaborator OTHER

  • Texas Children's Cancer Center

    collaborator OTHER

  • Children's Healthcare of Atlanta

    collaborator OTHER

  • C.S. Mott Children's Hospital

    collaborator OTHER

  • Children's Medical Center Dallas

    collaborator OTHER

  • Arkansas Children's Hospital Research Institute

    collaborator OTHER

  • Ann & Robert H Lurie Children's Hospital of Chicago

    collaborator OTHER

  • Children's Hospital of Michigan

    collaborator OTHER

  • Lucile Packard Children's Hospital

    collaborator OTHER

  • Seattle Children's Hospital

    collaborator OTHER

  • Children's Hospital of Philadelphia

    lead OTHER

Principal Investigators

  • Richard Aplenc, MD, PhD · Children's Hospital of Philadelphia

Eligibility

Min Age
8 Years
Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-01-03
Completion
2017-01-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02794207 on ClinicalTrials.gov